ClinicalTrials.gg
Sign In
RecruitingNCT05584293DIABASEUpdated Apr 19, 2024

DIABASE; Diabetes Mellitus Registry in Second Care

An observational study in Diabetes Mellitus, sponsored by Ziekenhuisgroep Twente. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Ziekenhuisgroep Twente · Observational

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to examine real world data from medical devices and clinical outcome from diabetes mellitus patients to gain the necessary insights to be able to improve individual patient care by building a registry.

02

Conditions studied

  • Diabetes Mellitus

Browse trials for

03

In context

Diabetes Mellitus

11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 234 across 2,254 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Ziekenhuisgroep Twente is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients with type 1 or type 2 diabetes mellitus.

Patients are recruited at the outpatient clinic of internal medicine, diabetes clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 1 or type 2 diabetes
  • Patients aged 18 years or older
  • Patients visiting the outpatient clinic internal medicine in the ZGT Hospital
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Severe general diseases or mental disorders making the participation in the study impossible
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,500 participants (estimated)
Target follow-up
30 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Real world data from medical devices and clinical outcome in a registry

    Examine real world data from medical devices and clinical outcome in a registry to gain the necessary insights to be able to improve individual patient care

    Time frame: 0-30 years

07

Study locations

1 of 1 sites recruiting
  • Ziekenhuisgroep Twente
    Almelo, Overijssel 7609PP, Netherlands
    • Thomas Urgert, MSc · Contact · t.urgert@zgt.nl · +31887083236
    • Goos Laverman, prof. dr. · Contact · g.laverman@zgt.nl · +31887083079
    • Goos Laverman, prof. dr. · Principal investigator
    • Thomas Urgert, MSc · Principal investigator
    Recruiting
08

References and documents

Publications

  • Urgert T, Kappert KDR, Veldhuis A, Geerdink J, van Beijnum BJF, Laverman GD. DIABASE: an automatically filled single-centre registry of diabetes mellitus in the Netherlands, combining clinical data with real-world longitudinal wearable device data-a study protocol. BMJ Open. 2025 Oct 13;15(10):e096888. doi: 10.1136/bmjopen-2024-096888. PubMed 41083304 ↗
  • den Braber N, Braem CIR, Vollenbroek-Hutten MMR, Hermens HJ, Urgert T, Yavuz US, Veltink PH, Laverman GD. Consequences of Data Loss on Clinical Decision-Making in Continuous Glucose Monitoring: Retrospective Cohort Study. Interact J Med Res. 2024 Jul 31;13:e50849. doi: 10.2196/50849. PubMed 39083801 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2050, 363 months after the start.

Of 630 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 130. This study's planned 363 months is above that.

Counting every sponsor, half of 771 studies reached it within 36 months; a quarter within 15 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Oct 18, 2022
StartActual
Sep 11, 2020
Primary completionEst.
Dec 31, 2050
CompletionEst.
Dec 31, 2060
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05584293
Lead sponsor
Ziekenhuisgroep Twente
Collaborators
University of Twente
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Sep 11, 2020
Primary completion
Dec 31, 2050 (estimated)
Completion
Dec 31, 2060 (estimated)
Last update
Apr 19, 2024

Study contacts

Thomas Urgert, MSc
Contact
t.urgert@zgt.nl
+31887083236

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus →

Other studies from this sponsor

Ziekenhuisgroep Twente

Start the discussion